, neurofibromin, and Gap1 function mutants of Ras and activated and inhibitory (Marshall, 1996) , which are negative regulators of Ras forms of various postulated target enzymes for Ras.
but could possibly influence Rho family proteins through Efficient transformation by Ras requires activation of the p120
GAP -associated protein p190, a Rho family GAP. other direct effectors in addition to the MAP kinase
Another family of putative Ras effectors, Ral.GDS, and kinase kinase Raf and is inhibited by inactivation of the two related proteins activate the Ras family member Ral PI 3-kinase pathway. Actin rearrangement correlates in response to activation of Ras (Urano et al., 1996) . At with the ability of Ras mutants to activate PI 3-kinase.
present, the function of Ral is unknown, although a role Inhibition of PI 3-kinase activity blocks Ras induction in the regulation of phospholipase D has been sugof membrane ruffling, while activated PI 3-kinase is gested. A protein that interacts with activated Ral has sufficient to induce membrane ruffling, acting through recently been identified (Cantor et al., 1995) that conRac. The ability of activated Ras to stimulate PI tains a Rac GAP domain, establishing another effector pathway by which Ras might perhaps be able to influ-3-kinase in addition to Raf is therefore important in ence the activity of Rho family proteins.
Ras transformation of mammalian cells and essential
In fission yeast, Ras has been shown to directly reguin Ras-induced cytoskeletal reorganization.
late two effectors. One is a MAP kinase kinase kinase, Byr2, the other is Scd1, a guanine nucleotide exchange Introduction factor for the Rho family protein Cdc42, which is involved in regulation of cell morphology (Chang et al., 1994) . In addition to their well characterized roles as inducers There is therefore a precedent for Ras directly controlof cellular proliferation, Ras proteins are known to have ling a Rho family exchange factor, although no such profound and rapid effects on the actin cytoskeleton;
connection has yet emerged in mammalian systems; both pathways are likely to be important in establishing yeast does not always accurately mirror mammalian and maintaining the transformed phenotype. When pathways, with adenylyl cyclase being a Ras effector in microinjected into fibroblasts, activated mutant Ras S. cerevisiae, but not in other species. protein induces membrane ruffling due to cortical actin One other mammalian Ras effector has been derearrangement within a few minutes (Bar Sagi and Fera- scribed that might be capable of mediating Ras control misco, 1986). Membrane ruffling or lamellipodia formaof the cytoskeleton. Phosphoinositide 3-OH kinase (PI tion is also induced by a number of growth factors and 3-kinase) interacts with Ras.GTP but not with Ras.GDP by microinjection of activated mutant Rac protein, a and is activated both in vitro and in vivo as a result of member of the Rho subfamily of Ras-related small this interaction (Kodaki et al., 1994 ; Rodriguez-Viciana GTPases . Since dominant-negative et al., 1994 Since dominant-negative et al., , 1996 . PI 3-kinase has been implicated in mutant Rac blocks induction of ruffling by Ras and by the regulation of the actin cytoskeleton by growth facgrowth factors, it is likely that Rac functions downstream tors such as PDGF and insulin (Kotani et al., 1994 ; Wennof Ras and growth factor receptors in the pathway leadströ m et al., 1994; Nobes et al., 1995) . ing to actin rearrangement. In Swiss 3T3 cells, Ras miMany mutations in the effector region of Ras, residues croinjection also leads to actin stress fiber formation 32-40, are known to inhibit the biological function of Ras through a Rho-mediated pathway that lies downstream and to block the interaction of Ras with target proteins. of Rac ). These observations proRecently, it has become clear that relatively subtle mutations in this region might lead to partial loss of function vide compelling, though indirect, evidence that Ras is Figure 1 . In Vitro Binding of Ras Mutants to Effectors (A) Mutant Ras proteins were loaded with GTP (T) or GDP (D) and bound to GST-fusion proteins of the effectors Ral.GDS (residues 1-97), c-Raf-1 (residues 1-259), and PI 3-kinase (full-length p110). Bound Ras was visualized by immunoblotting with monoclonal antibody Y13-259. In the control lane (cont), GST was substituted for effector fusion protein. All mutants were in a V12 background. (B) Ras mutant interaction with effectors was measured by scintillation proximity assay. GST-fusion proteins spanning the Ras-binding site in Ral.GDS and Raf were used. The means and standard errors of triplicate assays are shown.
mutants in which interaction with some effectors Spaargaren and Bischoff, 1994) . It is apparent that in most cases, Ras mutants show similar ability, maintained but with others is lost (Joneson et al., 1996; White et al., 1995) (see Discussion) . In this paper, we or lack of ability, to bind to these three effectors. A number, however, are capable of preferentially binding establish which mammalian effectors interact with the Ras partial loss of function mutants C40, G37, S35, and to one effector while failing to bind to the other two. In particular, E38 and S35 are able to bind to Raf-1 but E38. We use these mutants, plus activated versions of Ras effector pathways including Raf and phosphoinosinot significantly to Ral.GDS or p110␣, while G37 will bind to Ral.GDS but not to Raf-1 or p110␣, and C40 will tide 3-kinase (PI 3-kinase), to establish that at least two of these pathways need to be activated for efficient bind to p110␣ but not to Raf-1 or Ral.GDS. Each of the Ras mutants G37, E38, and C40 fail to show stimulation transformation of murine fibroblasts. Ras transformation is strongly inhibited by blocking PI 3-kinase activation.
of GTPase activity in response to the GTPase-activating proteins p120 GAP and neurofibromin, while S35 shows The mutants are also used to investigate the means by which Ras controls the actin cytoskeleton in mammalian marginal sensitivity to p120 GAP (data not shown). The use of only the Ras-binding site of Raf and Ral.GDS in these cells. PI 3-kinase is shown to be the effector by which Ras induces membrane ruffling, since Ras-induced rufbinding assays may have some limitations, particularly if additional sites of interaction with Ras exist: this apfling is blocked by inhibition of PI 3-kinase function, and PI 3-kinase activity is demonstrated to be sufficient to proach was used because of difficulties in obtaining active forms of the full-length proteins. In the case of cause membrane ruffling, in a manner involving Rac and a target of calphostin C. Activation of Raf or Ral.GDS p110␣, both full-length protein and the Ras-binding site alone (Rodriguez-Viciana et al., 1996) have been used is not sufficient to cause membrane ruffling.
to study Ras interactions with broadly similar results. The ability of these four Ras effector mutants, plus Results activated V12 Ras, to interact with the various Rasbinding proteins was investigated in more detail. A scinIn Vitro Interaction of Mutant Ras Proteins with Effectors tillation proximity assay (Skinner et al., 1994) was used to estimate the relative binding affinities of these Ras In order to gain further insight into the relative importance of the various different effectors of Ras, we have mutants for Raf-1 and Ral.GDS. As shown in Figure 1B , V12 Ras interacted strongly with Raf-1 in this assay: the screened a large array of Ras mutants for their ability to interact in vitro with the proven and suspected efaffinity of this interaction has been reported to be about 40 nM. No interaction could be seen with G37 and C40. fectors c-Raf-1, Ral.GDS, and PI 3-kinase p110␣ ( Figure  1A ). The PI 3-kinase used was full-length p85/GST-E38 interacted with Raf-1 with about a 5-fold-reduced affinity relative to V12, while S35 bound somewhat more p110␣ purified from a baculovirus expression system (Rodriguez-Viciana et al., 1996), while the Raf-1 and weakly. In the case of Ral.GDS, E38 and C40 showed no detectable binding, while the affinity of G37 binding Ral.GDS used were bacterially expressed GST-fusion proteins containing the Ras-binding site alone (Warne to Ral.GDS was reduced by about 3-fold relative to V12, Ras mutants (in a V12 background) were transfected into COS-7 cells. For PI 3-kinase, Ras mutants were transfected along with wild-type p110␣ or alone as indicated. p110* is the activated PI 3-kinase mutant K227E p110␣. PIP 3 levels were measured in whole cells 48 hr after transfection. Raf activity was measured by cotransfecting Ras mutants with epitope-tagged wild-type c-Raf-1. After 48 hr, the Raf was immunoprecipitated and assayed in a coupled assay for its ability to activate MEK. The means and standard errors of duplicate assays are shown. Representative of at least three experiments.
while that of S35 was reduced by more than 10-fold. also of activated effectors themselves, to transform NIH 3T3 cells was studied by focus formation assays. As The scintillation proximity assay proved to be unsuitable for studying the interaction of Ras with either PI 3-kinase shown in Figure 3A , none of the three Ras effector mutants G37, S35, and C40 in a V12 background were able or neurofibromin, possibly reflecting the relatively low affinities of these interactions, both around 200 nM. Preto induce transformation by themselves. However, as has been reported for G37 and S35 , vious use of this assay to study Ras interaction with neurofibromin relied on the use of L61 Ras, which has each pairwise combination of G37, S35, and C40 was able to induce transformation, albeit considerably less a higher affinity for GAPs (Skinner et al., 1994) . strongly than V12 Ras itself (in Figure 3 , 20 ng of V12 Ras plasmid was used, but 1.5 g of every other construct). It
Activation of Effectors by Ras Mutants in Intact Cells
is therefore likely that each of the three mutants is capable of activating a separate effector pathway, each of The ability of the Ras mutants described above to activate effector pathways was investigated in intact cells.
which can contribute to transformation. In these assays, we found that E38 behaved very similarly to S35 (data PI 3-kinase activation was investigated by transfecting Ras effector mutants, in a V12-activated background, not shown). The ability of downstream effectors of Ras to transinto COS cells along with the p110␣ catalytic subunit of PI 3-kinase. As reported previously (Rodriguez-Viciana form cells was also determined ( Figure 3A ). Raf activated by deletion of the amino-terminal regulatory region is a et al., 1994), V12 Ras synergizes strongly with PI 3-kinase expression to give greatly elevated levels of the weaker oncogene by itself than Ras, but it synergizes strongly with activated mutants of PI 3-kinase, Rac and lipid product phosphatidylinositol (3,4,5) trisphosphate (PIP 3 ). As shown in Figure 2 , S35, G37, and E38 Ras all Rho, none of which are transforming by themselves. Interestingly, PI 3-kinase will not synergize with Rac, failed to elevate PIP 3 levels in this assay, while C40 stimulated to about 35% of the level achieved with V12 suggesting that they function on the same pathway, but PI 3-kinase will synergize with Rho. Rac and Rho also Ras. The in vivo activity of these mutants thus mirrored their in vitro binding affinity for PI 3-kinase.
synergize in the transformation assay, suggesting that they are not acting in the same pathway. We were unable Raf activation by Ras mutants was also determined in COS cells by cotransfection of Ras mutants (in a V12 to see any effects of activated L72 Ral in these assays (data not shown). Cooperation of Ras effector mutants background) with tagged Raf (Leevers and Marshall, 1992) . V12 Ras strongly stimulates Raf, while G37 and with effectors themselves was also tested ( Figure 3B ). S35 Ras synergized with PI 3-kinase, Rac, and Rho, but C40 are entirely inactive. S35 and E38 Ras both activate Raf, but about 3-to 4-fold less strongly than V12. Again, not with Raf. C40 Ras synergized with Raf and Rho, but not with Rac or PI 3-kinase. G37 Ras synergized with the ability of Ras mutants to activate Raf in this cellbased assay correlates well with their in vitro binding Raf, Rac, and PI 3-kinase, and more weakly with Rho. From these data, it can be concluded that at least the to Raf.
Raf/MAP kinase pathway (activated by S35) and the PI 3-kinase/Rac pathway (activated by C40) act down-
Contribution of Ras Effector Pathways to Transformation
stream of Ras to induce transformation synergistically. The role of Ral.GDS in transformation is less clear: we In order to assess the importance of the various Ras effector pathways in fibroblast transformation, the abilwere unable to see any effects of activated Ral, but synergy between Ral and Raf has been reported recently ity of the Ras effector mutants described above, and therefore used the well characterized dominant-negative mutant of the PI 3-kinase regulatory subunit, p85, which lacks the binding site for the catalytic subunit, p110 . This dominant-negative PI 3-kinase (p85 ⌬iSH2-N, widely referred to elsewhere as ⌬p85) strongly inhibits transformation by V12 Ras, but not by v-Src, as assessed by focus formation ( Figure  4 ). The expression of this mutant, or any other form of p85, does not reduce the efficiency of formation and growth of drug-resistant colonies of these cells, either shown): the reduction in transformed foci is therefore 3T3 cells either alone or in combinations. Focus formation assays not due to a general toxicity resulting from inhibition of were performed over two weeks. The following Ras effectors and PI 3-kinase, but appears to be a specific effect on the other signaling proteins were assayed for transformation alone and ability of Ras, but not Src, to transform these cells. By in combination: ⌬1-295 Raf, K227E p110␣, V12 Rac, and V14 Rho. Assays were performed using 20 ng of V12 Ras plasmid and 1.5 g contrast, the strong inhibition of transformation by both of every other construct.
Ras and Src seen on coexpression of dominant-negative (B) Ras effector mutants in a V12 background were assayed for N17 Rac is accompanied by a very marked reduction, transformation in combination with ⌬1-295 Raf, V12 Rac, V14 Rho, greater than 80%, in drug-resistant colony formation, and K227E p110␣. Assays were performed using 20 ng of V12 Ras suggesting that expression of N17 Rac is inhibitory for plasmid and 1.5 g of every other construct.
normal as well as transformed cell growth (data not shown). As would be expected, dominant-negative MEK, an inhibitor of the Raf/MAP kinase pathway, signif- (Urano et al., 1996) . It is possible that Ral.GDS activates other targets in addition to Ral, and also that G37 might icantly blocks Ras transformation, showing that the Raf pathway is also critical for Ras transformation. interact with other unknown effectors in addition to Ral.GDS.
In addition to p85 ⌬iSH2-N, the inhibitory ability of full-length p85 and also mutants lacking the Bcr-related Rho GAP-like region (p85 ⌬bcr) or a region in the interRas Transformation Requires PI 3-Kinase Function SH2 domain C-terminal to the p110 interaction site (p85 ⌬iSH2-C) were also tested. All three of these inhibited A direct way of testing the hypothesis that the PI 3-kinase pathway is important in the transformation of Ras, but not Src, transformation. Overexpression of fulllength p85 inhibits PI 3-kinase signaling, albeit less cells by Ras is to determine the effect of inhibition of this enzyme on V12 Ras transformation of NIH 3T3 cells. strongly than p85 with the p110 interaction site deleted (Kodaki et al., 1994 and our unpublished data), probably The long-term nature of transformation assays means that the use of chemical inhibitors of PI 3-kinase, particuby titering out stimulatory molecules that bind to the regulatory subunit in much the same way in which p85 larly unstable ones such as wortmannin, is not ideal. We to inhibit filopodia formation induced by extracellular , 1994) . However, LY294002 had absolutely no effect on the activation of the MAP kinase ERK2 in response to PDGF or ⌬iSH2-N does. Presumably, some productive comphorbol ester in these cells (data not shown). Ruffling plexes with p110 will form, but at high levels of p85 induced by V12 Ras was not fully blocked by LY294002, expression, these will be effectively removed from upalthough some clear diminution of the extent of ruffling stream signaling by competition from free p85. The Bcrwas reproducibly noticed. V12 Rac-induced ruffling was related region of p85 has been reported to interact with unaffected by LY294002. For all of these experiments, the Rho family proteins Cdc42 and Rac (Zheng et al., similar effects to LY294002 were also seen with wort-1994); the fact that p85 ⌬bcr has identical activity to mannin, an unrelated inhibitor of PI 3-kinase activity p85 and p85 ⌬iSH2-N in this assay suggests that direct (data not shown). It therefore appears that PI 3-kinase, interaction of p85 with Rac or Cdc42 is not likely to be and not Raf or Ral.GDS, is one of the Ras effectors a critical part of the mechanism of Ras transformation.
involved in the induction of cortical actin rearrangement, The expression of the SH2 and SH3 domains of p120 GAP membrane ruffling, and lamellipodia formation. Howdoes not inhibit Ras transformation, suggesting that the ever, it is possible that another ruffling pathway also inhibitory effect of p85 is not nonspecific due to overexexists that is activated by V12 Ras but not V12 C40 Ras pression of any SH2 and SH3 domains.
and is insensitive to chemical inhibitors of PI 3-kinase. To confirm the inhibitory effect of blocking PI 3-kinase To further investigate this PI 3-kinase inhibitorfunction on the ability of oncogenic Ras to transform resistant pathway linking Ras to Rac and membrane cells, NIH 3T3 cell lines stably transformed by V12 Ras ruffling, the effects of a number of other inhibitors on were infected with retroviruses expressing dominantRas-induced membrane ruffling were studied. The p85-negative p85 constructs. Drug-resistant pools of inderived dominant-negative PI 3-kinase constructs were fected cells were assayed for their ability to grow in coexpressed in PAE cells with activated Ras or Rac. suspension in soft agar. As shown in Table 1, expression As shown in Figure 6B , expression of p85 totally and of either full-length p85␣ or p85␤, or ⌬p85␣, all substanreproducibly blocked V12 Ras-induced membrane ruftially inhibited colony formation of Ras-transformed fling. In addition, p85 ⌬iSH2-N, p85 ⌬bcr, and p85 cells in soft agar. Expression of these constructs had ⌬iSH2-C all completely inhibited V12 Ras-induced rufno significant effects on v-Src-induced anchorage-indefling. These constructs also block PDGF-induced rufpendent cell growth.
fling (Wennströ m et al., 1994 and data not shown). The p120 GAP SH2 and SH3 construct was without effect.
Involvement of Ras Effector Pathways
The effect of these p85-based dominant-negative PI in Cytoskeletal Reorganization 3-kinase constructs appeared to be specific for RasMicroinjection of activated Ras protein or cDNA into and growth factor-induced ruffling, since they had absoporcine aortic endothelial (PAE) cells induces rapid cortilutely no effect on ruffling induced by V12 Rac (Figure cal actin rearrangement and membrane ruffling. Expres-6B and data not shown). These data indicate that the sion vectors for the various Ras effector mutants, and mechanism by which Ras controls the actin cytoskelethe activated effectors themselves, were injected into ton through Rac is entirely dependent on normal PI PAE cells and the cells subsequently stained with phal-3-kinase function acting upstream of Rac. The inability loidin-rhodamine to visualize F actin. As shown in Figure  of chemical inhibitors of PI 3-kinase to inhibit fully Ras-5A, while activated V12 Ras gave strong membrane rufinduced actin rearrangement may suggest that drugfling, S35 and G37 Ras in V12 backgrounds failed to resistant forms of PI 3-kinase couple to Ras. induce actin rearrangements. V12 C40 Ras induced As shown in Figure 6C , the protein kinase C inhibitor membrane ruffling, although more weakly than V12 Ras.
calphostin C was a very good inhibitor of ruffling induced It therefore appears likely that PI 3-kinase is a downboth by Ras and by PDGF in PAE cells. Calphostin C was stream effector involved in Ras-induced ruffling. An actialso able to fully inhibit activated PI 3-kinase-induced vated mutant of PI 3-kinase was sufficient to cause ruffling. However, another protein kinase C inhibitor, the membrane ruffling. Activated Rac gave strong ruffling, bisindoylmaleimide GF 109203X, was not effective. The while activated Raf-CAAX and L72 Ral did not. PI inhibitor GF 109203X was used under conditions where 3-kinase-induced ruffling was inhibited by coexpression it inhibited phorbol ester activation of ERK2 (data not of dominant-negative N17 Rac, but not dominant-negashown). Since calphostin C acts on diacyl glyceroltive N17 Ras or N17 Cdc42, while V12 Ras-induced binding zinc fingers, while bisindoylmaleimide acts on ruffling was sensitive to dominant-negative Rac but not the kinase domain, it is possible that a diacyl glycerolbinding protein other than a protein kinase C family Cdc42 ( Figure 5B ). This N17 Cdc42 construct was able member is important in the control of membrane ruffling: LY294002 fails to do so, COS cells were transfected with V12 Ras in the presence or absence of p85 or possible candidates include the Rho family exchange factors Vav, Vav2, FGD1, and Lfc. Calphostin C was ⌬p85. The cells were then metabolically labeled with 32 P-orthophosphate, and PIP 3 levels were determined. unable to inhibit ruffling induced by activated Rac, placing the target for this drug downstream of Ras and PI As shown in Figure 7B , both p85 and ⌬p85 were able to almost completely reverse V12 Ras-induced elevation 3-kinase and upstream of Rac.
of PI 3-kinase lipid products. These constructs did not influence Ras expression levels (data not shown).
Effect of LY294002 on PDGF-and Ras-Induced Cellular PIP3 Levels
The data in Figure 6B raises the possibility that Ras may Discussion be capable of affecting the activity of PI 3-kinases that are not fully sensitive to chemical inhibitors such as
The various partial loss of function mutants of Ras used in this paper help to define the effector pathways acting LY294002 and wortmannin. To further explore this possibility, the effect of LY294002 on the levels of PI 3-kinasedownstream of Ras. It is clear that Ras can trigger multiple signaling pathways in addition to the well characterproduced lipids was investigated in NIH 3T3 cells ( Figure  7A ). PDGF-induced PIP 3 elevation is entirely reversed ized Raf/MAP kinase cascade Joneson et al., 1996; Marshall, 1996) . We describe here the by treatment of cells with 20 M LY294002, a dosage that should entirely inhibit the activity of p110␣ (Vlahos ability of four different effector site mutants of Ras to stimulate known effectors: C40 Ras interacts with PI et al., 1994) . When V12 Ras was expressed in these cells, the levels of PIP3 were constitutively elevated to 3-kinase, G37 Ras interacts with Ral.GDS, and S35 and E38 Ras interact with Raf. None of these mutants interabout half the peak level achieved with PDGF. This elevation of PIP3 was, however, substantially resistant to act productively with p120 GAP or neurofibromin. The ability of these mutants to interact with other potential mamthe effects of the drug; even extended treatment with very high concentrations of LY294002 left about half this malian effectors of Ras is not known. S35 Ras has previously been reported to interact selectively with Raf, level of PIP 3 . It is therefore likely that Ras couples to forms of PI 3-kinase that are resistant to this drug, and but not with the unrelated MAP kinase kinase kinase, Byr2, from Schizosaccharomyces pombe, while G37 also activates conventional drug-sensitive isoforms.
To confirm that expression of the regulatory p85 subRas interacts with Byr2 but not with Raf : together, the two synergize strongly in transforunit of PI 3-kinase can block the ability of V12 Ras to induce elevated levels of PIP 3 in intact cells, even though mation of NIH 3T3 cells, as also shown here. The mutant C40 has been reported to be unable to activate Raf, but Ral.GDS, and activated PI 3-kinase synergizes with Rho and Raf, but not with Rac. We were unable to find effects is able to induce membrane ruffling by an unknown mechanism, while S35 fails to cause membrane ruffling of activated Ral on transformation: Ral.GDS may activate other targets in addition to Ral, or Ral.GDS may but activates Raf (Joneson et al., 1996) . Very recently, it has been demonstrated that Ras can use unidentified not be the only effector binding to G37 Ras. It appears that at least two effector pathways need pathways other than the Raf/MAP kinase pathway to cause transformation of murine fibroblasts (Khosravito be activated by Ras for transformation to result. These pathways can be Raf plus PI 3-kinase, or Raf or PI Far et al., 1996) . It has also been shown that the V12 G37 mutant Ras is capable of interacting with Ral.GDS 3-kinase plus Ral.GDS, or another effector capable of binding to G37 Ras. Even so, the synergistic transforma- .
Since Ras mutants that activate only Raf, such as E38 tion seen with two different Ras mutants or effectors in Figure 3 falls well short of the efficiency of transformaand S35, are very poorly transforming, it would appear that activation of endogenous Raf protein alone is not tion seen with V12 Ras alone. This may reflect the fact that the partial loss of function effector mutants of Ras sufficient to transform murine fibroblasts, even though overexpression of strongly activated Raf is transforming are significantly compromised in their ability to activate even the effectors with which they still interact (see by itself, possibly through a mechanism involving secretion of autocrine growth factors (McCarthy et al., 1995) . Figures 1B and 2 ). It may also be the case that more than two effector pathways need to be activated for The Raf mutant used in this study, which has had its amino terminal regulatory domain deleted, is relatively truly high efficiency transformation. However, the fact that dominant-negative forms of PI 3-kinase based on weakly activated, as it is not membrane localized. Reasonable transformation is achieved by the Ras mutants the p85 regulatory subunit are able to inhibit V12 Ras transformation very significantly indicates that this paththat activate only Raf in synergy either with Ras mutants that activate Ral.GDS or PI 3-kinase or with activated way is one of those normally used by Ras oncogenes to establish the transformed cell phenotype. Transfor-PI 3-kinase, Rac, or Rho. Similarly, the Ras mutant that activates only PI 3-kinase synergizes with those activatmation by v-Src appears to be much less sensitive to inhibition of PI 3-kinase signaling: this may reflect the ing other pathways, including the one that activates only acts upstream of Rho Ridley and Hall, 1992) . This apparent inconsistency may reflect differences in cell types or, perhaps more likely, differences in the nature of the biological assay: it is possible that distinct pools of Rho and Rac GTPases exist, with those proteins involved in actin rearrangement being differently regulated from those involved in, for example, transcriptional regulation. Transformation is likely to reflect all aspects of Rac and Rho signaling, not just cytoskeletal effects.
The definition of a set of effector mutants of Ras that each engage only one effector pathway allows one to demonstrate that multiple pathways are required for efficient transformation of fibroblasts. However, are these mutants able to provide information about the mechanism by which Ras acts to give a specific short-term biological response? In the case of Ras induction of membrane ruffling and lamellipodia, it has been shown that activated Ras induces very strong ruffling through a Rac-mediated pathway . We have shown here that activated PI 3-kinase also induces membrane ruffling, again through a Rac-mediated mechanism. The only Ras partial loss of function mutant to cause ruffling is C40: this, together with the inability of Raf or Ral to cause ruffling, rules out Raf and Ral.GDS as effectors on the ruffling pathway. Since C40 Ras stimulates PI 3-kinase and causes membrane ruffling in an LY294002-and wortmannin-sensitive manner in PAE cells, it is very likely that this mutant is causing ruffling through interaction with a drug-sensitive PI 3-kinase.
In contrast to C40 Ras-induced ruffling, V12 Rasinduced ruffling is not fully sensitive to PI 3-kinase inhibitors in porcine aortic endothelial cells ( Figure 6A ) or in Swiss 3T3 cells (C. D. Nobes and A. Hall, personal communication) . This has previously been interpreted as evidence that Ras controls Rac-dependent ruffling by a PI 3-kinase-independent mechanism. However, the use of a different means of inhibiting PI 3-kinase function, expression of dominant-negative constructs based is not required for inhibition of Ras-induced ruffling, and (B) V12 Ras and PI 3-kinase constructs, including wild-type p110, p85 constructs do not inhibit Rac-induced ruffling, it is were transfected into COS-7 cells. PIP3 levels were measured in unlikely that direct interaction of p85 with GTP-bound whole cells 48 hr after transfection.
Rac or Cdc42 is responsible for this inhibition (Zheng et al., 1994) . The exact mechanism by which overexpresfact that v-Src uses several signaling pathways to transsion of p85 mutants interferes with PI 3-kinase has not form cells, only some of which involve Ras. Src may be been defined, but is likely to involve titering out upstream also able to control PI 3-kinase in a Ras-independent signaling molecules that are needed for activation of PI manner.
3-kinase both by receptor tyrosine kinases and by Ras. Looking further down the effector pathways, Raf can As shown in Figure 7B , overexpression of p85 or ⌬p85 synergize with Rac or Rho, as shown previously by othdoes indeed inhibit the ability of V12 Ras to activate PI ers (Khosravi-Far et al., 1995; Qiu et al., 1995a Qiu et al., , 1995b , 3-kinase in whole cells, as determined by measuring and PI 3-kinase can synergize with Rho, but not with PIP 3 levels. Although Ras directly interacts with and Rac. This suggests that Rac and PI 3-kinase lie on the moderately activates p110 in vitro, it is likely that in order same pathway, most likely with PI 3-kinase acting upto achieve efficient activation of PI 3-kinase by V12 Ras stream of Rac (Hawkins et al., 1995) , but that Rho lies in whole cells, at least basal levels of other signals are on a different pathway; this ties in with the ability of also required, including one mediated by p85. EndogeRac and Rho to synergize with each other in causing nous p110 is likely to be effectively uncoupled from transformation. Placing Rac and Rho on different pathstimulatory signals feeding into p85 by massive overexways differs from the model derived from actin cytoskeleton rearrangements in Swiss 3T3 cells in which Rac pression of this protein.
Overexpression of Ras and of p85 have previously been shown to exert opposing influcontrols more than one pathway comes from a combination of genetic and two-hybrid analysis in yeast, particuences on mammalian PI 3-kinase activity in a model system in S. pombe (Kodaki et al., 1994) Kit (Pharmacia) . For bacterial expression, a BamH1 site was added data), although none of these are known to be resistant in-frame to the second codon by PCR and the inserts cloned into to these drugs. Measurement of PIP 3 levels in V12 Ras the pGEX (Pharmacia) and pRSET (Invitrogen) vectors for expression as GST-and histidine-tagged fusion proteins, respectively. To have expressing NIH 3T3 cells shows that the Ras-induced, the effector mutants on a G12 background for GAP assays, the V12 but not PDGF-induced, elevation of this lipid is partially mutation was mutated back to G12 by PCR and the inserts cloned resistant to treatment of cells with LY294002 ( Figure 7 ).
into the pRSET vector. Fusion proteins were purified according to A novel C2 domain containing PI 3-kinase isoform has the manufacturer's protocols. The p110K227E mutant has been derecently been reported that is about fifty times less senscribed elsewhere (Rodriguez-Viciana et al., 1996) . p85␣wt, p85 sitive than p110␣ to wortmannin (Virbasius et al. 1996) . in response to PDGF (Klinghofer et al., 1996) . In the colonies were selected and, when confluent, the medium was colcase of Swiss 3T3 cells, PDGF-induced ruffling does not lected and frozen as aliquots in the presence of polybrene.
appear to be inhibited by neutralizing Ras antibodies ; however, in MDCK cells, hepatocyte
Ras/Effector In Vitro Binding Assay
growth factor-induced ruffling is entirely sensitive to Ras-binding assays were carried out as described in Warne et al. these Ras antibodies . In both cases, (1993) and Rodriguez-Viciana et al. (1994) . Ras (0.5 M) and effector-GST (0.5 g) were used in a 200 l assay. Scintillation Proximity Rac function is required for ruffling to occur. We have Assay was performed as described in Skinner et al. (1994) .
found that the ability of anti-Ras antibodies or N17 Ras to inhibit ruffling varies greatly with cell type and the
Measurement of Raf and PI 3-Kinase Activity
nature of the external stimulus. It is clear that there are in COS-7 Cells multiple pathways leading to PI 3-kinase activation: in Constructs were electroporated into COS-7 cells as described presome cases, Ras is necessary; in other cases, it is not.
viously . After 48 hr, PI 3-kinase A very similar situation has been described for growth activity was assayed in the absence of serum by measuring 3Ј phosphorylated phosphoinositide lipids, as described by Carter and factor induction of ERK2 MAP kinase in fibroblasts, in Downes (1992) . Raf activity was assayed in the absence of serum by which Ras is required for PDGF-and insulin-induced, cotransfecting a Myc-tagged c-Raf-1 construct and by performing a but not EGF-induced, activation in Rat-1 and NIH 3T3
coupled MEK/ERK2 kinase assay on 9E10 immunoprecipitates as fibroblasts, but both PDGF-and EGF-induced ERK2 acdescribed by Leevers and Marshall (1992 For the data in Figures 3 and 4 , low passage NIH 3T3 cells were seeded at 1.25 ϫ 10 5 cells per well in 6-well dishes the day before
The possibility that endogenous Ras normally actilipofection with 1.5 g of each plasmid, apart from V12 Ras plasmid, vates multiple effector pathways is supported by the in which 20 ng was used, using the Tfx-50 reagent (Promega) acobservation that, in a number of mammalian systems, cording to the manufacturer's protocols. Two days later, the cells Ras function is required for growth factor activation of were transferred to 10 cm plates. After reaching confluence, they PI 3-kinase (Rodriguez-Viciana et al., 1994; Klinghofer were kept for two weeks in DME medium containing 5% calf serum, et al., 1996) as well as Raf (Marshall, 1996) . Probably after which they were stained with 0.5% crystal violet. For study of inhibitory effects on transformation, 40 ng of V12 Ras or 20 ng the most compelling evidence to date that Ras normally
